Published 2 days ago • loading... • Updated 2 days ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Will sell 10,250,000 shares and warrants priced at $0.98 per share under Nasdaq rules, aiming to raise approximately $10 million before fees and expenses.
The offering is expected to close on March 25, 2025, pending customary conditions being met.

Insights by Ground AI

Does this summary seem wrong?

56 Articles

All

Left

Center

Right

The Berkshire Eagle

+54 Reposted by 54 other sources

Center

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common…

2 days ago

Read Full Article

pressreach.com

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PressReach

BOSTON, March 23, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The w…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year